Biochemistry and clinical applications of ribavirin.
作者信息
Gilbert B E, Knight V
出版信息
Antimicrob Agents Chemother. 1986 Aug;30(2):201-5. doi: 10.1128/AAC.30.2.201.
Abstract
摘要
相似文献
1
Biochemistry and clinical applications of ribavirin.利巴韦林的生物化学及临床应用
Antimicrob Agents Chemother. 1986 Aug;30(2):201-5. doi: 10.1128/AAC.30.2.201.
2
Ribavirin: beginning the blitz on respiratory viruses?利巴韦林：开启对呼吸道病毒的“闪电战”？
Pediatr Infect Dis. 1985 Nov-Dec;4(6):668-71. doi: 10.1097/00006454-198511000-00014.
3
Clinical review of ribavirin.利巴韦林的临床综述
Infect Control. 1987 May;8(5):215-8. doi: 10.1017/s0195941700065978.
4
Prospects for broad-spectrum chemotherapy of serious viral respiratory infections.
JAMA. 1983 May 20;249(19):2689-90.
5
Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study.雾化吸入利巴韦林治疗呼吸道合胞病毒感染婴儿。一项随机双盲研究。
N Engl J Med. 1983 Jun 16;308(24):1443-7. doi: 10.1056/NEJM198306163082403.
6
Ribavirin for influenza and respiratory syncytial virus infections.利巴韦林用于流感和呼吸道合胞病毒感染。
Lancet. 1983 Sep 3;2(8349):554-5.
7
Ribavirin (Virazole).利巴韦林（病毒唑）。
Med Lett Drugs Ther. 1986 Apr 25;28(712):46-7.
8
Ribavirin in respiratory syncytial virus infection. A double blind placebo controlled trial is needed.利巴韦林用于呼吸道合胞病毒感染。需要进行一项双盲安慰剂对照试验。
Arch Dis Child. 1988 Aug;63(8):986-90. doi: 10.1136/adc.63.8.986.
9
Ribavirin aerosol for acute bronchiolitis.用于急性细支气管炎的利巴韦林气雾剂。
Arch Dis Child. 1986 Jun;61(6):593-7. doi: 10.1136/adc.61.6.593.
引用本文的文献
1
The Overview of Potential Antiviral Bioactive Compounds in Poxviruses.痘病毒中具有潜在抗病毒活性的生物化合物概述。
Adv Exp Med Biol. 2024;1451:331-336. doi: 10.1007/978-3-031-57165-7_21.
2
Kill or corrupt: Mechanisms of action and drug-resistance of nucleotide analogues against SARS-CoV-2.杀伤或灭活：核苷类似物抗 SARS-CoV-2 的作用机制和耐药性。
Antiviral Res. 2023 Feb;210:105501. doi: 10.1016/j.antiviral.2022.105501. Epub 2022 Dec 22.
3
Current Insights and Molecular Docking Studies of the Drugs under Clinical Trial as RdRp Inhibitors in COVID-19 Treatment.在 COVID-19 治疗中作为 RdRp 抑制剂处于临床试验阶段的药物的最新研究进展和分子对接研究。
Curr Pharm Des. 2022;28(46):3677-3705. doi: 10.2174/1381612829666221107123841.
4
Bedd. root-derived flavonoids as prominent antiviral agents against Newcastle disease virus.来自床根的类黄酮作为抗新城疫病毒的重要抗病毒剂。
RSC Adv. 2020 Sep 10;10(55):33534-33543. doi: 10.1039/d0ra01820a. eCollection 2020 Sep 7.
5
Advances in Antiviral Therapy for Subacute Sclerosing Panencephalitis.抗亚急性硬化性全脑炎病毒治疗的进展。
Molecules. 2021 Jan 15;26(2):427. doi: 10.3390/molecules26020427.
6
Evaluation of the potency of FDA-approved drugs on wild type and mutant SARS-CoV-2 helicase (Nsp13).评估 FDA 批准的药物对野生型和突变型 SARS-CoV-2 解旋酶（Nsp13）的效力。
Int J Biol Macromol. 2020 Nov 15;163:1687-1696. doi: 10.1016/j.ijbiomac.2020.09.138. Epub 2020 Sep 24.
7
Drug treatment of coronavirus disease 2019 (COVID-19) in China.中国对 2019 冠状病毒病（COVID-19）的药物治疗。
Eur J Pharmacol. 2020 Sep 15;883:173326. doi: 10.1016/j.ejphar.2020.173326. Epub 2020 Jun 27.
8
Molecular Targets in the Chemotherapy of Coronavirus Infection.冠状病毒感染的化学疗法中的分子靶标。
Biochemistry (Mosc). 2020 May;85(5):523-530. doi: 10.1134/S0006297920050016.
9
Community-Acquired Respiratory Paramyxovirus Infection After Allogeneic Hematopoietic Cell Transplantation: A Single-Center Experience.异基因造血细胞移植后社区获得性呼吸道副粘病毒感染：单中心经验
Open Forum Infect Dis. 2018 Apr 12;5(5):ofy077. doi: 10.1093/ofid/ofy077. eCollection 2018 May.
10
Advanced Prodrug Strategies in Nucleoside and Non-Nucleoside Antiviral Agents: A Review of the Recent Five Years.核苷类和非核苷类抗病毒药物的高级前药策略：对最近五年的综述。
Molecules. 2017 Oct 16;22(10):1736. doi: 10.3390/molecules22101736.
本文引用的文献
1
Amantadine and ribavirin aerosol treatment of influenza A and B infection in mice.金刚烷胺和利巴韦林气雾剂对小鼠甲型和乙型流感感染的治疗作用
Antimicrob Agents Chemother. 1980 Apr;17(4):642-8. doi: 10.1128/AAC.17.4.642.
2
Lack of effect of oral ribavirin in naturally occurring influenza A virus (H1N1) infection.口服利巴韦林对自然发生的甲型流感病毒（H1N1）感染无效。
J Infect Dis. 1980 May;141(5):548-54. doi: 10.1093/infdis/141.5.548.
3
Plasma disappearance, urine excretion, and tissue distribution of ribavirin in rats and rhesus monkeys.利巴韦林在大鼠和恒河猴体内的血浆清除、尿液排泄及组织分布
Antimicrob Agents Chemother. 1981 Jun;19(6):1042-9. doi: 10.1128/AAC.19.6.1042.
4
In vivo inhibition of respiratory syncytial virus by ribavirin.利巴韦林对呼吸道合胞病毒的体内抑制作用。
Antimicrob Agents Chemother. 1982 Jan;21(1):125-30. doi: 10.1128/AAC.21.1.125.
5
Lassa virus infection of rhesus monkeys: pathogenesis and treatment with ribavirin.恒河猴感染拉沙病毒：发病机制及利巴韦林治疗
J Infect Dis. 1980 May;141(5):580-9. doi: 10.1093/infdis/141.5.580.
6
Hematological and bone marrow effects of ribavirin in rhesus monkeys.利巴韦林对恒河猴的血液学和骨髓影响。
Toxicol Appl Pharmacol. 1984 Jun 30;74(2):163-72. doi: 10.1016/0041-008x(84)90139-x.
7
Enhanced treatment of Lassa fever by immune plasma combined with ribavirin in cynomolgus monkeys.免疫血浆联合利巴韦林对食蟹猴拉沙热的强化治疗
J Infect Dis. 1984 Mar;149(3):420-7. doi: 10.1093/infdis/149.3.420.
8
Treatment of intracranial dengue virus infections in mice with a lipophilic derivative of ribavirin.用利巴韦林的亲脂性衍生物治疗小鼠颅内登革病毒感染。
Antimicrob Agents Chemother. 1983 Jul;24(1):134-6. doi: 10.1128/AAC.24.1.134.
9
Determination of ribonucleoside triphosphate pools in influenza A virus-infected MDCK cells.甲型流感病毒感染的犬肾传代细胞中三磷酸核糖核苷库的测定
Arch Virol. 1983;77(2-4):223-9. doi: 10.1007/BF01309269.
10
Broad-spectrum antiviral activity of 2-beta-D-ribofuranosylselenazole-4-carboxamide, a new antiviral agent.新型抗病毒药物2-β-D-呋喃核糖基硒唑-4-甲酰胺的广谱抗病毒活性
Antimicrob Agents Chemother. 1983 Sep;24(3):353-61. doi: 10.1128/AAC.24.3.353.
Zotero 插件